U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07103668) titled 'A Phase II Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients' on July 17.
Brief Summary: An open-label, randomized, comparative phase II study including patients with CLDN18.2-positive unresectable locally advanced gastric cancer. To evaluate the objective response rate (ORR) and progression-free survival (PFS) of IMC002 compared with investigator's choice of treatment (ICT) as third-line or later therapy in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with positive CLDN18.2 expression.
Study Start Date: July 31, 2026
Study Ty...